Trial Profile
Tailoring Treatment with Tirofiban in patients showing Resistance to aspirin and/or Resistance to clopidogrel: 3T/2R
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Tirofiban (Primary)
- Indications Coronary artery disease; Coronary disorders; Embolism and thrombosis; Myocardial infarction; Myocardial reperfusion injury
- Focus Therapeutic Use
- Acronyms 3T/2R; TREND-AR
- 30 Jun 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 30 Jun 2009 Results were published in Circulation.
- 12 Feb 2009 New source identified and integrated (publication of trial design and protocol).